- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advancing Hematologic Care and the Future of Shared Decision-Making
Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence future clinical practices and shared decision-making models, while identifying key areas for further research and collaboration to improve patient outcomes.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- In what ways do these studies’ data collectively advance our understanding of unmet needs in hematologic cancer management, and how can their findings shape future clinical practices?
- How can the findings presented at ASH 2024 shape the next generation of shared decision-making models for patients with hematologic cancers?
- What are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL
May 1st 2025Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Read More
Statins May Improve Survival Among Patients With CLL/SLL Receiving Ibrutinib
May 1st 2025The findings come from a review of 4 randomized clinical trials, which found that statin use at the start of treatment was associated with improved cancer-related survival, overall survival, and progression-free survival.
Read More
